The value of anti-müllerian hormone (AMH) as a marker of the ovarian reserve is becoming
clear in a range of clinical contexts. This study reports the external validation of a quadratic …

Objectives: Despite ample evidence of variation in timing of menopause, little is known
about the extent or underlying causes of individual variation in ovarian reserve and age …

BACKGROUND The measurement of circulating anti-Müllerian hormone (AMH) has been
applied to a wide array of clinical applications, mainly based on its ability to reflect the …

Context Antimüllerian hormone (AMH) levels are higher in patients with polycystic ovary
syndrome (PCOS). Accumulating evidence indicates that AMH has an impact on the …

Abstract Objective The World Health Organization (WHO) has defined three classes of
anovulatory infertility, based on serum gonadotrophin and oestradiol levels: low …

Background Anti-Müllerian hormone (AMH) is a product of growing ovarian follicles. The
concentration of AMH in blood may also reflect the non-growing follicle (NGF) population, ie …

BACKGROUND: The study aim was to compare the relationship between serum anti‐
Müllerian hormone (AMH) levels and other markers of ovarian function with early antral …

Anti-Müllerian hormone (AMH) concentrations correlate with the number of antral follicles
as well as age and constitute an endocrine marker for ovarian aging. In normogonadotropic …

Background Anti-Müllerian hormone (AMH) is currently used as an ovarian reserve marker
for individualized fertility counseling, but very little is known of individual AMH decline in …

Objective: The aim of this study was to assess the capability of a single measurement of
antimüllerian hormone (AMH) to predict menopause status in late reproductive-aged …